Details of Disease

General Information of Disease (ID: DIS0UVDG)

• Disease Name: Squamous head and neck cell carcinom
• Disease Class: 2D60: Metastatic lymph node neoplasm
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DIS0UVDG: Squamous head and neck cell carcinom
• ICD Code:
  ICD-11: ICD-11: 2D60.0
  ICD-10: ICD-10: C77.0
• Disease Identifiers:
  MONDO ID: MONDO_0010150
  MESH ID: D000077195
  UMLS CUI: C1168401
  OMIM ID: 275355
  MedGen ID: 257911
  SNOMED CT ID: 716659002

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 10 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AT-406	DMVJW0S	Phase 3	Small molecular drug	[1]
SD-101	DMAMTGI	Phase 3	Oligonucleotide	[2]
GSK3359609	DM4WYGA	Phase 2/3	Antibody	[3]
Eftilagimod alpha	DML4BT1	Phase 2	Recombinant?protein	[4]
MK-1454	DMEDITW	Phase 2	NA	[5]
PQR309	DMMCYZ8	Phase 2	Small molecular drug	[6]
XL880	DMHJTR2	Phase 2	Small molecular drug	[7]
Pepinemab	DM03GDJ	Phase 1/2	Antibody	[8]
GEN-011	DMNELKW	Phase 1	Cell therapy	[9]
REGN6569	DM0ZMNI	Phase 1	Antibody	[10]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] ClinicalTrials.gov (NCT04459715) A Study of Debio 1143 (Xevinapant) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy. U.S. National Institutes of Health.
• [2] ClinicalTrials.gov (NCT02521870) A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT04128696) Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (INDUCE-3). U.S. National Institutes of Health.
• [4] ClinicalTrials.gov (NCT03625323) Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC (TACTI-002). U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT04220866) Study of Intratumoral (IT) MK-1454 in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002). U.S. National Institutes of Health.
• [6] ClinicalTrials.gov (NCT03740100) Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations (HNSCC). U.S. National Institutes of Health.
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5679).
• [8] ClinicalTrials.gov (NCT04815720) Pepinemab in Combination With Pembrolizumab in Advanced, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE B84). U.S. National Institutes of Health.
• [9] ClinicalTrials.gov (NCT04596033) TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy. U.S. National Institutes of Health.
• [10] ClinicalTrials.gov (NCT04465487) Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies. U.S. National Institutes of Health.